Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

598 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Among authors: feagan bg. Lancet. 2024 Dec 17:S0140-6736(24)01927-5. doi: 10.1016/S0140-6736(24)01927-5. Online ahead of print. Lancet. 2024. PMID: 39706209
A randomized phase 2 study of efmarodocokin alfa, an IL-22 agonist, versus vedolizumab in patients with ulcerative colitis.
Danese S, Rothenberg ME, Lim JJ, Ding HT, McBride JM, Chen Y, Dash A, Mar JS, Keir M, Peyrin-Biroulet L, Panes J, Colombel JF, Feagan B, Valentine JF, Schreiber S. Danese S, et al. Among authors: feagan b. Clin Gastroenterol Hepatol. 2024 Dec 16:S1542-3565(24)01096-6. doi: 10.1016/j.cgh.2024.11.013. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 39694207 Free article.
Discordance between MR enterography and endoscopic detection of Crohn's disease ileal strictures: evidence to inform recommendations.
Yalon M, Mohammadinejad P, Inoue A, Takahashi H, Ehman EC, Esquivel A, Fletcher EC, Behnke CJ, Lee YS, Fidler JL, Hansel SL, Jairath V, Feagan BG, Rieder F, Baker ME, Bruining DH, Fletcher JG. Yalon M, et al. Among authors: feagan bg. Abdom Radiol (NY). 2024 Dec 18. doi: 10.1007/s00261-024-04721-x. Online ahead of print. Abdom Radiol (NY). 2024. PMID: 39692760
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.
D'Haens G, Taxonera C, Lopez-Sanroman A, Nos P, Danese S, Armuzzi A, Roblin X, Peyrin-Biroulet L, West R, Mares WGN, Duijvestein M, Gecse KB, Feagan BG, Zou G, Hulshoff MS, Mookhoek A, Oldenburg L, Clasquin E, Bouhnik Y, Laharie D. D'Haens G, et al. Among authors: feagan bg. Lancet Gastroenterol Hepatol. 2025 Jan;10(1):26-33. doi: 10.1016/S2468-1253(24)00317-0. Epub 2024 Nov 18. Lancet Gastroenterol Hepatol. 2025. PMID: 39571587 Clinical Trial.
Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies.
Atreya R, Ferrante M, Panaccione R, Feagan B, Shchukina O, Jairath V, Rieder F, Hisamatsu T, Siegmund B, Kligys K, Song A, Zambrano J, Mallick M, Zhang Y, Armuzzi A, D'Haens G. Atreya R, et al. Among authors: feagan b. J Crohns Colitis. 2024 Nov 1:jjae164. doi: 10.1093/ecco-jcc/jjae164. Online ahead of print. J Crohns Colitis. 2024. PMID: 39485390
Erratum for: Reliability of MR Enterography Features for Describing Fibrostenosing Crohn Disease.
Rieder F, Baker ME, Bruining DH, Fidler JL, Ehman EC, Sheedy SP, Heiken JP, Ream JM, Holmes DR 3rd, Inoue A, Mohammadinejad P, Lee YS, Taylor SA, Stoker J, Zou G, Wang Z, Rémillard J, Carter RE, Ottichilo R, Atkinson N, Siddiqui MT, Sunkesula VC, Ma C, Parker CE, Panés J, Rimola J, Jairath V, Feagan BG, Fletcher JG; Stenosis Therapy and Anti-Fibrosis Research (STAR) Consortium. Rieder F, et al. Among authors: feagan bg. Radiology. 2024 Oct;313(1):e249020. doi: 10.1148/radiol.249020. Radiology. 2024. PMID: 39470432 Free PMC article. No abstract available.
Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: A post hoc analysis from the SELECTION study.
Schreiber S, Feagan BG, Louis E, Hisamatsu T, Hibi T, Dron L, Jamoul C, Patel H, Harris K, Taliadouros V, Oortwijn A, Peyrin-Biroulet L. Schreiber S, et al. Among authors: feagan bg. United European Gastroenterol J. 2024 Nov;12(9):1243-1255. doi: 10.1002/ueg2.12686. Epub 2024 Oct 25. United European Gastroenterol J. 2024. PMID: 39452892 Free PMC article. Clinical Trial.
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement.
Lu C, Rosentreter R, Parker CE, Remillard J, Wilson SR, Baker ME, Bhatnagar G, Begun J, Bruining DH, Bryant RV, Christensen B, Feagan BG, Fletcher JG, Gordon I, Henderson G, Jairath V, Knudsen J, Kucharzik T, Lesack K, Maaser C, Maconi G, Novak K, Rimola J, Taylor SA, Wilkens R, Rieder F; Stenosis Therapy and Anti-Fibrotic Research (STAR) consortium. Lu C, et al. Among authors: feagan bg. Lancet Gastroenterol Hepatol. 2024 Dec;9(12):1101-1110. doi: 10.1016/S2468-1253(24)00265-6. Epub 2024 Oct 22. Lancet Gastroenterol Hepatol. 2024. PMID: 39447590
598 results